BioNTech

aid: biontech
url: https://raw.githubusercontent.com/api-evangelist/biontech/refs/heads/main/apis.yml
name: BioNTech
type: Index
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/biontech.png
tags:
- Biotechnology
- Pharmaceuticals
- mRNA
- Vaccines
- Oncology
- Immunotherapy
- Healthcare
description: BioNTech is a Mainz-based biotechnology company that pioneered the use of messenger RNA (mRNA) technology in
  human therapeutics. Best known for co-developing Comirnaty, the COVID-19 mRNA vaccine with Pfizer, BioNTech is building
  a broad oncology pipeline across mRNA cancer immunotherapies, next-generation immunomodulators such as the bispecific antibody
  BNT327, and targeted therapies, as well as continuing infectious disease vaccine development. BioNTech does not currently
  expose a public developer API; this index captures the company's products, pipeline, clinical trials, and corporate resources
  as an API Evangelist profile.
created: '2026-05-23'
modified: '2026-05-23'
specificationVersion: '0.19'
apis: []
common:
- type: DomainSecurity
  url: security/biontech-domain-security.yml
- type: LinkedIn
  url: https://www.linkedin.com/company/biontech-se
- type: Website
  url: https://biontech.com/
- type: Investors
  url: https://investors.biontech.de/
- type: MedicalAffairs
  url: https://medical.biontech.com/
  title: BioNTech for Healthcare Professionals
- type: ClinicalTrials
  url: https://clinicaltrials.biontech.com/
- type: Careers
  url: https://jobs.biontech.com/
- type: News
  url: https://biontech.com/us/en/home/media.html
- type: PressReleases
  url: https://investors.biontech.de/news-releases
- type: Blog
  url: https://biontech.com/us/en/home/mediaroom/news.html
- type: PrivacyPolicy
  url: https://biontech.com/int/en/home/privacy-statement.html
- type: TermsOfService
  url: https://biontech.com/int/en/home/imprint.html
- type: Features
  data:
  - name: mRNA Platform
    description: Proprietary messenger RNA platform underlying Comirnaty and the company's broader vaccine and oncology pipeline
  - name: Comirnaty
    description: COVID-19 mRNA vaccine co-developed and commercialized in collaboration with Pfizer
  - name: Oncology Pipeline
    description: Three complementary modalities across mRNA cancer immunotherapies, next-generation immunomodulators, and
      targeted therapies
  - name: BNT327
    description: Next-generation bispecific antibody candidate binding PD-L1 and VEGF-A for synergistic cancer treatment
  - name: mRNA Cancer Immunotherapies
    description: Individualized neoantigen cancer immunotherapies targeting residual tumor cells in adjuvant settings
  - name: Infectious Diseases Pipeline
    description: Vaccine candidates extending the mRNA platform to additional high-burden infectious diseases
- type: UseCases
  data:
  - name: COVID-19 Vaccination
    description: Continued supply of Comirnaty COVID-19 vaccine across global markets
  - name: Cancer Immunotherapy
    description: 25+ Phase 2/3 oncology clinical trials and 10+ novel combination trials
  - name: Pandemic Preparedness
    description: Application of mRNA platform to rapidly developable vaccines against emerging infectious disease threats
  - name: Healthcare Professional Information
    description: Dedicated medical affairs portal providing scientific and clinical data to clinicians
- type: Integrations
  data:
  - name: Pfizer Collaboration
    description: Long-running co-development and commercialization partnership for Comirnaty and other mRNA programs
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com